Thr64
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr64  -  MAF1 (human)

Site Information
EALsPPQtsGLsPsR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3211923

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 3 ) , mass spectrometry ( 1 , 2 , 4 , 5 ) , mutation of modification site ( 3 ) , western blotting ( 3 )
Disease tissue studied:
bone cancer ( 3 ) , osteosarcoma ( 3 ) , leukemia ( 5 ) , chronic myelogenous leukemia ( 5 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
mTOR (human) ( 3 )
Treatments:
MMS ( 2 ) , temsirolimus ( 3 ) , WYE132 ( 3 )

Downstream Regulation
Effects of modification on biological processes:
transcription, induced ( 3 )

References 

1

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

2

Michels AA, et al. (2010) mTORC1 directly phosphorylates and regulates human MAF1. Mol Cell Biol 30, 3749-57
20516213   Curated Info

3

Shor B, et al. (2010) Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J Biol Chem 285, 15380-92
20233713   Curated Info

4

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

5

Stokes M (2008) CST Curation Set: 4392; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info